Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference87 articles.
1. Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe CC, Ferrario A, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018;6:328. https://doi.org/10.3389/fpubh.2018.00328.
2. Organisation for Economic Co-operation and Development. Pharmaceutical spending. 2018. https://www.oecd-ilibrary.org/social-issues-migration-health/pharmaceutical-spending/indicator/english_998febf6-en. Accessed September 2019.
3. Prasad V, Wang R, Afifi SH, Mailankody S. The rising price of cancer drugs-a new old problem? JAMA Oncol. 2017;3(2):277–8. https://doi.org/10.1001/jamaoncol.2016.4275.
4. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 2014;15(3):e112–8. https://doi.org/10.1016/s1470-2045(13)70578-3.
5. Espin J, Schlander M, Godman B, Anderson P, Mestre-Ferrandiz J, Borget I, et al. Projecting pharmaceutical expenditure in EU5 to 2021: adjusting for the impact of discounts and rebates. Appl Health Econ Health Policy. 2018;16(6):803–17. https://doi.org/10.1007/s40258-018-0419-1.